Literature DB >> 1506862

Imipramine induced lipidosis and dexamethasone effect: morphological and biochemical study in normal and chronic GM2 gangliosidosis fibroblasts.

S Palmeri1, L Mangano, C Battisti, A Malandrini, A Federico.   

Abstract

A large heterogeneous group of lysosomotropic compounds with a common cationic amphiphilic structure induces in vitro and in vivo lysosomal lipid storage. The biochemical mechanism underlying the lipidosis is still the subject of investigation. The authors report the experimental effect of imipramine and dexamethasone on lysosomal system in cultured skin fibroblasts. Morphological and ultrastructural observations of cells treated with imipramine showed vacuoles with lipidic storage, enlarged lysosomes with electron translucent zones and normal appearance of all the other cytoplasmic organelles. The lysosomal enzyme activities were decreased on biochemical study. On the contrary, an increased enzyme activity was detected in the culture medium. Pretreatment with dexamethasone partially prevented the effect of imipramine. Our results suggest that tricyclic antidepressants may induce lysosomal lipidosis through a dysfunction in the recycling of mannose-6-phosphate receptors and in the trafficking of newly synthesized lysosomal enzymes. Moreover the data presented may provide a clue in understanding some of the side effects observed in patients chronically treated with antidepressant drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1506862     DOI: 10.1016/0022-510x(92)90030-o

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  1 in total

1.  GM2 gangliosidosis AB variant: first case of late onset and review of the literature.

Authors:  Benjamin Ganne; Benjamin Dauriat; Laurence Richard; Foudil Lamari; Karima Ghorab; Laurent Magy; Mehdi Benkirane; Alexandre Perani; Valentine Marquet; Patrick Calvas; Catherine Yardin; Sylvie Bourthoumieu
Journal:  Neurol Sci       Date:  2022-08-04       Impact factor: 3.830

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.